5nance5nance
5nance5nance
HomeScreens
LOGINGET FREE ACCOUNT

Kilitch Drugs (India) Ltd.

•
kilitch.comBSE: 524500NSE: KILITCH
Market Cap₹ 653 Cr.
Current Price
High / Low₹ 220 / 117
Stock P/E20.0
Book Value₹ 97
Price to Book1.34
Dividend Yield0.00 %
ROCE12.4 %
ROE11.1 %
Face Value₹ 10

Add ratio to table

ABOUT

AI Sector View

AI GENERATED

Healthcare

Buy

This stance relies on proxies and positioning because no direct pharma-export or healthcare operating series exists in the dataset. The depreciated currency at 95.23 (Sep/26) can support export earnings, inflation at 4.45% (Jul/26) is manageable for a defensive sector, and consumer spending remains large at INR 44743 billion (Jun/26). Strong FPI inflow of INR 10620 crore over 3 months to 2026-08-31 from INR -11381 crore in the prior 3 months adds a real sector-specific tailwind, but confidence stays capped because the fundamental drivers are indirect proxies.

Confidence
50%
View full sector analysis →

PROS

  • Company has delivered good profit growth of 39.4% CAGR over last 5 years
  • Latest quarter profit grew 954.7% YoY, showing strong momentum
  • Company has delivered good sales growth of 21.9% CAGR over last 5 years
  • Company comfortably covers its interest (14.1x coverage)
  • Attractively priced for its growth - PEG of 0.7
  • Company maintains a comfortable, low leverage position

CONS

  • Receivables are growing faster than sales - a possible quality concern
  • A large part of profit comes from other income (33.3% of PBT)
  • Poor cash conversion - profits are not backed by operating cash flow (CFO/PAT 0.31x)
  • Free cash flow has been persistently negative
  • Total debt has risen sharply - up 80.0% year on year

* The pros and cons are machine generated based on quantitative rules.

Peer comparison

HealthcareHealthcarePharmaceuticals & Drugs
Part ofNIFTY 50NIFTY 500NIFTY LARGEMIDCAP 250NIFTY 100NIFTY 200
S.No.Name
1.SUNPHARMA1842.0036.54441957.500.872901.2326.5315299.8810.9819.1128.81
2.DIVISLAB9326.0084.64247576.000.32902.0065.503080.0027.8021.5140.75
3.TORNTPHARM4975.0086.76189233.010.76566.003.284921.0057.3219.2733.81
4.ZYDUSLIFE1119.5024.74111670.550.09990.20-34.908017.0023.9721.3924.54
5.CIPLA1365.0032.72110272.680.95785.55-39.187119.284.1316.0016.73
6.LAURUSLABS1970.3597.37106460.420.10362.07123.942026.3129.1018.2031.50
7.DRREDDY1161.0030.0796906.380.69435.60-69.108099.80-5.2113.7510.63
8.AUROPHARMA1675.4525.9796401.690.241032.0325.229150.3517.4412.7620.54
9.LUPIN2096.0017.3495842.920.861416.9816.018276.8934.2828.8629.59
10.MANKIND2277.0046.0494050.370.04574.0929.124030.5912.8913.2426.30
11.GLENMARK2416.9037.9468210.880.10482.83927.884018.4831.3520.3520.03
12.KILITCH186.9021.74653.430.0019.67769.58448.79940.3114.506.54
Detailed Comparison with:

Quarterly Results

Standalone Figures in Rs. Crores / View Consolidated

Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
313230393345475634384572409
262626343040384231343952375
Operating Profit5645368144461934
OPM %16.83%18.09%13.50%13.34%9.63%12.35%17.44%24.69%10.46%9.71%12.81%27.05%8.31%
11313622482135
Interest0010000111115
Depreciation0000000101118
Profit before Tax6675611101561061969
Tax %24.91%28.50%16.41%30.80%27.55%16.45%27.73%24.20%19.90%13.51%20.75%27.57%27.29%
Net Profit4464497115951451
2.692.603.482.262.525.504.287.072.985.272.744.081.45

Profit & Loss

Standalone Figures in Rs. Crores / View Consolidated

Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026TTM
2850966170105118132182189564
294581606594100111150155501
Operating Profit-161615111720313363
OPM %-2.03%11.06%16.17%1.92%7.61%10.58%14.72%15.52%17.14%17.59%11.15%
23664556141446
Interest00111112237
Depreciation11111111229
Profit before Tax-0720581419234142105
Tax %92.09%13.42%24.37%14.65%18.02%24.41%19.19%24.75%23.43%22.03%25.64%
Net Profit-061546111618313278
EPS0.000.000.000.003.986.7610.0910.9319.379.27—
Dividend Payout %0.00%11.08%5.20%0.00%0.00%0.00%0.00%0.00%0.00%0.00%—

COMPOUNDED SALES GROWTH

10 Years:
25%
5 Years:
22%
3 Years:
17%

COMPOUNDED PROFIT GROWTH

10 Years:
—
5 Years:
39%
3 Years:
27%

STOCK PRICE CAGR

10 Years:
28%
5 Years:
17%
3 Years:
20%
1 Year:
2%

RETURN ON EQUITY

10 Years:
7%
5 Years:
10%
3 Years:
11%
Last Year:
11%

Balance Sheet

Standalone Figures in Rs. Crores / View Consolidated

Corporate actions

2026

Mar 24

1:1

Quarterly Results & Increase in Authorised Capital & Bonus issue

Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Equity Capital13141515151616161635
104114135135147160175206237298
11913152022314988
Trade Payables6858142829264768
4862489566
Total Liabilities128144171173195231250285355495
878871415162020
Capital Work in Progress0000001647140
9610110098107117110121121124
335645241512
00000006283117
Cash & Bank2443621819710
192955597292104586172
Total Assets128144171173195231250285355495

Cash Flows

Standalone Figures in Rs. Crores / View Consolidated

Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
1-112107810-31512
Cash from Investing-1-2-22-10-5-166-9-41-96
Cash from Financing-06151283111686
-020-13-3150-112

Ratios

Standalone Figures in Rs. Crores / View Consolidated

Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026

Shareholding Pattern

Numbers in percentages

Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
69.2369.2369.2369.2363.7763.7763.7763.77
0.000.000.000.000.000.000.000.12
DIIs0.000.000.000.000.000.000.000.00
Government0.000.000.000.000.000.000.000.00
30.7630.7730.7730.7636.2336.2336.2236.11

Documents

Corporate disclosures, annual reports, credit ratings, and concall transcripts

2026-08-27
Shareholders meeting

2026-08-27 - Kilitch Drugs (India) Limited has submitted the Exchange a copy Srutinizers report of Annual General Meeting held on August 27, 2026

2026-08-27
Shareholders meeting

2026-08-27 - Kilitch Drugs (India) Limited has informed the Exchange regarding Proceedings of Annual General Meeting held on August 27, 2026

2026-08-18
Monitoring Agency Report

2026-08-18 - We are submitting herewith monitoring agency report

2026-08-18
Copy of Newspaper Publication

2026-08-18 - Kilitch Drugs (India) Limited has informed the Exchange about Copy of Newspaper Publication

2026-08-13
Outcome of Board Meeting

2026-08-13 - Kilitch Drugs (India) Limited has submitted to the Exchange, the financial results for the period ended Jun 30, 2026.

2026-08-04
Copy of Newspaper Publication

2026-08-04 - Kilitch Drugs (India) Limited has informed the Exchange about Copy of Newspaper Publication

2026-08-01
Updates

2026-08-01 - Kilitch Drugs (India) Limited has informed the Exchange regarding 'AGM Notice and Annual Report - Physical Intimation to Shareholders'.

2026-08-01
Updates

2026-08-01 - Kilitch Drugs (India) Limited has informed the Exchange regarding 'Intimation of Book Closure for the purpose of AGM'.

2026-08-01
Shareholders meeting

2026-08-01 - Kilitch Drugs (India) Limited has informed the Exchange regarding Notice of Annual General Meeting to be held on August 27, 2026

News

Recent coverage and analyst commentary for KILITCH

Loading news…

🤖

AI Stock Analyst

Kilitch Drugs (India) Ltd.

🔒

Sign in to Chat with AI

Log in with your 5nance account to ask institutional questions about performance, financials, and outlook.

✨ Sign In to Chat

Free 5nance Account

5nance5nance

Stock analysis and screening tool

5nanceAI © 2020-2026

Made with ❤️ in India.

Data provided by Accord Fintech

Terms & Privacy.

Product

PremiumWhat's new?Learn

Team

About usSupport

Theme

5nance5nance

Product

PremiumWhat's new?Learn

Team

About usSupport

Theme

5nanceAI © 2020-2026

Data provided by Accord Fintech

Made with ❤️ in India.

HomeScreens
Login